What is the primary objective of GMP?

The primary objective of GMP is to ensure products are consistently produced and controlled to meet predefined quality standards, preventing contamination, mix-ups, mislabeling, and variability through preventive controls rather than end-product testing alone. This spans the "5 Ps"—People, Products, Procedures, Processes, and Premises—covering raw materials, facilities, equipment, personnel training, documentation, validation, and distribution traceability, as codified in FDA 21 CFR Parts 210/211 and EU EudraLex Volume 4.

Who is legally or professionally required to comply with GMP?

GMP compliance is legally required for manufacturers of pharmaceuticals, biologics, APIs, and related products under FDA 21 CFR Parts 210/211, EU EudraLex Volume 4, and WHO GMP guidelines. This includes contract manufacturers (CMOs), API producers (ICH Q7), and supply chain partners handling materials, with sponsors retaining oversight responsibility via quality agreements and audits; medical devices follow aligned QSR (21 CFR Part 820), while cosmetics and food have sector-specific rules.

Does GMP require an external audit or third-party certification?

GMP does not universally mandate third-party certification but requires internal audits, self-inspections, and readiness for unannounced regulatory inspections by authorities like FDA or EMA. Organizations must maintain independent Quality Control Units (FDA §211.22) or Qualified Persons (EU Annex 16) for batch release, with PIC/S and MRAs enabling mutual recognition; WHO GMP often serves as a procurement baseline without formal certification.

How often should an assessment for GMP be performed?

GMP assessments, including internal audits and self-inspections, must be conducted at planned intervals based on risk, with annual Product Quality Reviews (PQR) required under FDA §211.180(e) and EU GMP Chapter 1. Ongoing monitoring via CAPA, change control, environmental checks, and management reviews ensures continual improvement; requalification triggers (e.g., maintenance, changes) dictate ad-hoc reassessments per EU Annex 15.

What are the consequences of non-compliance with GMP?

Non-compliance with GMP results in regulatory actions including FDA Form 483 observations, Warning Letters, import alerts, product seizures, recalls, fines up to $50,000 per day, and potential consent decrees or criminal prosecution. Historical cases like Elixir Sulfanilamide (1937, 100+ deaths) underscore risks of contamination; modern enforcement blocks market access, incurs multimillion-dollar remediation, and exposes management to liability.

Can GMP be mapped to other international frameworks?

Yes, GMP aligns closely with ICH Q10 Pharmaceutical Quality System, ICH Q9 Quality Risk Management, and PIC/S guidelines for global harmonization. FDA 21 CFR Parts 210/211 map to EU GMP Chapters 1-6 and WHO GMP via shared pillars like PQS, validation (EU Annex 15), and computerized systems (EU Annex 11); MRAs reduce redundant audits across jurisdictions.

What is the first step to begin implementing GMP?

The first step to implement GMP is conducting a comprehensive gap analysis against applicable regulations like FDA 21 CFR Parts 210/211 or EU EudraLex Volume 4, prioritizing risks via Quality Risk Management (ICH Q9). This informs a Validation Master Plan (VMP), executive sponsorship, and remediation roadmap covering the 5 Ps.

What is the primary objective of EU AI Act?

The primary objective of the EU AI Act is to establish a risk-based regulatory framework that prohibits unacceptable-risk AI practices, imposes strict obligations on high-risk AI systems, mandates transparency for limited-risk systems, and fosters trustworthy AI while protecting health, safety, and fundamental rights. Regulation (EU) 2024/1689, effective 1 August 2024, classifies AI into four tiers via Articles 5–6 and Annexes I/III, requiring providers and deployers to ensure conformity through lifecycle controls like risk management (Article 9) and post-market monitoring (Article 72).

Who is legally or professionally required to comply with EU AI Act?

Providers, deployers, importers, distributors, and authorized representatives are legally required to comply with the EU AI Act when placing AI systems on the EU market or using their outputs in the EU. Article 3 defines providers as those developing or marketing systems under their name; deployers as professional users (Article 3(4)). Extraterritorial scope captures third-country entities (Article 2); high-risk obligations (Articles 16–17) apply to Annex III uses like biometrics and employment.

Does EU AI Act require an external audit or third-party certification?

The EU AI Act requires conformity assessments for high-risk systems, which may involve third-party notified bodies and external audits depending on classification. Article 43 mandates internal (Annex VI) or third-party (Annex VII) assessments; notified bodies (Articles 28–39) issue certificates for certain Annex III systems, enabling CE marking (Article 48) and EU database registration (Article 49). Quality management systems (Article 17) undergo periodic surveillance audits.

How often should an assessment for EU AI Act be performed?

Assessments for the EU AI Act must be performed before placing high-risk systems on the market, after substantial modifications, and continuously via post-market monitoring. Article 61 requires conformity reassessment post-modification (Article 3(23)); providers maintain ongoing risk management (Article 9) and monitoring plans (Article 72), with serious incident reporting (Article 73) and logs retained per Article 19 (minimum six months).

What are the consequences of non-compliance with EU AI Act?

Non-compliance with the EU AI Act incurs tiered administrative fines up to 7% of worldwide annual turnover or €40 million for prohibited practices, plus market bans and corrective actions. Chapter XII (Article 99) sets penalties: up to 7% for Article 5 bans, 3% for high-risk obligations, 2% for others; enforced by national authorities (Article 70) with AI Office oversight for GPAI (Article 101), including system withdrawal and personal liability.

Can EU AI Act be mapped to other international frameworks?

Yes, the EU AI Act can be mapped to other international frameworks through harmonized standards that create presumption of conformity. Article 40 enables standards (e.g., for Article 15 cybersecurity) to align with existing schemes; its risk-based structure and controls like RMS (Article 9) support integration with global AI management systems, though sector-specific analysis is needed for full interoperability.

What is the first step to begin implementing EU AI Act?

The first step to implement the EU AI Act is to conduct an AI inventory and risk classification against prohibited practices (Article 5) and high-risk criteria (Article 6, Annexes I/III). Map all systems/models to roles (provider/deployer), document decisions, and prioritize prohibitions (effective February 2025) and GPAI obligations (August 2025).

Standards Comparison

GMP vs EU AI Act

GMP

Mandatory

1963

Global standards ensuring pharmaceutical manufacturing quality control

EU AI Act

Mandatory

2024

EU regulation for risk-based AI safety and governance

Quick Verdict

GMP ensures consistent manufacturing quality in pharma via preventive controls and validation, while EU AI Act regulates high-risk AI systems with conformity assessments and risk management. Companies adopt GMP for patient safety and market access; AI Act for legal compliance and trust.

Manufacturing Quality

GMP

Good Manufacturing Practice (GMP)

Cost

€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Mandates independent quality unit batch release authority
Requires validated processes preventing contamination and mix-ups
Enforces risk-based Quality Risk Management proportionality
Demands comprehensive documentation ensuring traceability and integrity
Establishes facility controls for environmental contamination prevention

Artificial Intelligence

EU AI Act

Regulation (EU) 2024/1689 Artificial Intelligence Act

Cost

€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Risk-based classification into four tiers
Prohibited unacceptable-risk AI practices
High-risk conformity assessment and CE marking
GPAI systemic risk evaluations and reporting
Lifecycle risk management and post-market monitoring

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

GMP Details

What It Is

Good Manufacturing Practice (GMP) is a regulatory framework establishing minimum standards for manufacturing controls in pharmaceuticals, biologics, and related sectors. Its primary purpose is ensuring products are consistently produced to quality standards via preventive systems. Key approach is risk-based (QRM) with Pharmaceutical Quality System (PQS) lifecycle management, spanning materials to distribution.

Key Components

Core pillars: 5 Ps (People, Premises, Processes, Procedures, Products)
Elements include validated processes, independent Quality Control Unit, documentation, training, facility controls, CAPA, change control
Built on ICH Q9/Q10, regional codes like FDA 21 CFR 211, EU EudraLex Volume 4
Compliance via inspections, no central certification but enforced regionally

Why Organizations Use It

Legal mandate protects patients, prevents recalls; reduces liability, ensures market access. Strategic benefits: supply reliability, efficiency, reputation. Builds stakeholder trust through proven state of control.

Implementation Overview

Phased: gap analysis, Validation Master Plan, qualification (IQ/OQ/PQ), training, audits. Applies to pharma manufacturers globally; high resource needs for facilities, systems.

EU AI Act Details

What It Is

EU AI Act (Regulation (EU) 2024/1689) is a comprehensive EU regulation establishing the first horizontal framework for AI governance. It adopts a risk-based approach, prohibiting unacceptable-risk practices, regulating high-risk systems with lifecycle controls, imposing transparency on limited-risk AI, and minimally regulating others. Scope covers providers, deployers, and value-chain actors for AI systems used in the EU.

Key Components

**Four risk tiersProhibited (Article 5), high-risk (Annexes I/III, Articles 6-15), limited-risk (transparency, Article 50), minimal-risk.
Core high-risk requirements: risk management (Article 9), data governance (Article 10), documentation (11-13), human oversight (14), cybersecurity (15).
GPAI obligations (Chapter V), conformity assessment, CE marking, EU database registration.
Built on product-safety principles; presumption of conformity via harmonized standards.

Why Organizations Use It

Mandatory for EU market access, avoiding fines up to 7% global turnover.
Enhances risk management, trust, and competitiveness in sectors like employment, healthcare, law enforcement.
Builds stakeholder confidence through transparency and accountability.

Implementation Overview

Phased: prohibitions (6 months), GPAI (12 months), high-risk (24-36 months post-1 Aug 2024).
Inventory AI assets, classify risks, build compliance systems, conduct assessments.
Applies to all sizes targeting EU; audits via notified bodies for high-risk.

Key Differences

Aspect	GMP	EU AI Act
Scope	Manufacturing controls for pharmaceuticals, biologics, APIs	Risk-based AI systems lifecycle governance
Industry	Pharma, biologics, medical devices, cosmetics, food	All sectors using AI: finance, healthcare, employment, law enforcement
Nature	Mandatory enforceable manufacturing standards	Mandatory EU regulation with conformity assessments
Testing	Process/equipment validation, IQ/OQ/PQ, audits	Conformity assessments, notified bodies, post-market monitoring
Penalties	Warning letters, recalls, import alerts	Fines up to 7% global turnover, market bans

Scope

GMP

Manufacturing controls for pharmaceuticals, biologics, APIs

EU AI Act

Risk-based AI systems lifecycle governance

Industry

GMP

Pharma, biologics, medical devices, cosmetics, food

EU AI Act

All sectors using AI: finance, healthcare, employment, law enforcement

Nature

GMP

Mandatory enforceable manufacturing standards

EU AI Act

Mandatory EU regulation with conformity assessments

Testing

GMP

Process/equipment validation, IQ/OQ/PQ, audits

EU AI Act

Conformity assessments, notified bodies, post-market monitoring

Penalties

GMP

Warning letters, recalls, import alerts

EU AI Act

Fines up to 7% global turnover, market bans

Frequently Asked Questions

Common questions about GMP and EU AI Act

GMP FAQ

EU AI Act FAQ

You Might also be Interested in These Articles...

The NIS2 "FTE Trap": Why 5 Analysts for 24/7 Security is Actually 8 (and Why the Board Needs to Know)

Exposed: NIS2 FTE Trap math shows 5 analysts fail 24/7 coverage due to sickness, training, leave & 2026 churn. Line-by-line breakdown for compliance. Alert your

One Step at a Time - a 6 Month Plan to Live and Breath DORA

Achieve DORA compliance in 6 months with our detailed plan. Learn implementation sequence, starting steps, pitfalls to avoid, and accelerators for success. Toug

The Human-AI Synergy: How Modern Compliance Tools Amplify Your Team's Strategic Impact

Unlock human-AI synergy with modern compliance tools. Automate monitoring, cut non-compliance risks 3x, and boost strategic decision-making. Elevate your team's

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how GMP and EU AI Act compare against other standards

Other GMP Comparisons

Other EU AI Act Comparisons

What It Is

Key Components

Core pillars: 5 Ps (People, Premises, Processes, Procedures, Products)

Elements include validated processes, independent Quality Control Unit, documentation, training, facility controls, CAPA, change control

Built on ICH Q9/Q10, regional codes like FDA 21 CFR 211, EU EudraLex Volume 4

Compliance via inspections, no central certification but enforced regionally

What It Is

Key Components

**Four risk tiersProhibited (Article 5), high-risk (Annexes I/III, Articles 6-15), limited-risk (transparency, Article 50), minimal-risk.

Core high-risk requirements: risk management (Article 9), data governance (Article 10), documentation (11-13), human oversight (14), cybersecurity (15).

GPAI obligations (Chapter V), conformity assessment, CE marking, EU database registration.

Built on product-safety principles; presumption of conformity via harmonized standards.

Aspect

GMP

EU AI Act

Scope

Manufacturing controls for pharmaceuticals, biologics, APIs

Risk-based AI systems lifecycle governance

Industry

Pharma, biologics, medical devices, cosmetics, food

All sectors using AI: finance, healthcare, employment, law enforcement

Nature

Mandatory enforceable manufacturing standards

Mandatory EU regulation with conformity assessments

Testing

Process/equipment validation, IQ/OQ/PQ, audits

Conformity assessments, notified bodies, post-market monitoring

Penalties

Warning letters, recalls, import alerts

Fines up to 7% global turnover, market bans